These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 263185)

  • 1. [Intellectual deterioration in Parkinson patients treated with L-dopa. Long-term prognostic factors].
    Bonduelle M; Degos CF
    Int J Neurol; 1979; 13(1-4):255-61. PubMed ID: 263185
    [No Abstract]   [Full Text] [Related]  

  • 2. Dementia and treatment with L-dopa in Parkinson's disease.
    Hietanen M; Teräväinen H
    Mov Disord; 1988; 3(3):263-70. PubMed ID: 3193964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mental impairment in Parkinson's disease. The role of anticholinergic drugs.
    Meco G; Casacchia M; Lazzari R; Franzese A; Castellana F; Carta A; Iannuccelli M; Agnoli A
    Acta Psychiatr Belg; 1984; 84(4):325-35. PubMed ID: 6507124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term prognostic factors in Parkinson's disease (author's transl)].
    Guillard A; Chastang C
    Rev Neurol (Paris); 1978 May; 134(5):341-54. PubMed ID: 725403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Hely MA; Morris JG; Reid WG; Trafficante R
    Mov Disord; 2005 Feb; 20(2):190-9. PubMed ID: 15551331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The deterioration of patients with parkinsonism treated with L-dopa].
    Guillard A
    Nouv Presse Med; 1975 Oct; 4(35):2503-6. PubMed ID: 1196872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [An analysis of long-term L-dopa treatment on 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?].
    Indo T; Takahashi A
    Rinsho Shinkeigaku; 1986 Apr; 26(4):363-71. PubMed ID: 3731637
    [No Abstract]   [Full Text] [Related]  

  • 8. [Early or late onset of L-dopa treatment in Parkinson disease?].
    von Kummer R; Schneevoigt K
    Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131
    [No Abstract]   [Full Text] [Related]  

  • 9. The relationship of the basic intellectual endowment of the Parkinson patient to the long-term effect of L-dopa.
    Boshes B; Arbit J; Blonsky ER; Dolkart M
    Int J Neurol; 1979; 13(1-4):181-98. PubMed ID: 263183
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mental disorders in patients with Parkinson's disease treated with L-dopa].
    Piccirilli M; Piccinin GL
    Clin Ter; 1981 Jun; 97(5):473-9. PubMed ID: 7273659
    [No Abstract]   [Full Text] [Related]  

  • 12. [Tiapride in persistent dyskinesias following long-term L-dopa for parkinsonism].
    Arlazoroff A; Flechtir S; Goldexberg E; Bleicher Z; Barber Y
    Harefuah; 1985 Mar; 108(5):227-9. PubMed ID: 4007677
    [No Abstract]   [Full Text] [Related]  

  • 13. [Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications].
    Guillard A; Chastang C; Fenelon G
    Rev Neurol (Paris); 1986; 142(3):207-14. PubMed ID: 3797924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 15. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
    Bouhaddi M; Vuillier F; Fortrat JO; Cappelle S; Henriet MT; Rumbach L; Regnard J
    Auton Neurosci; 2004 Nov; 116(1-2):30-8. PubMed ID: 15556835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mental disorders in Parkinson's disease after treatment with L-DOPA.
    Rondot P; de Recondo J; Coignet A; Ziegler M
    Adv Neurol; 1984; 40():259-69. PubMed ID: 6695602
    [No Abstract]   [Full Text] [Related]  

  • 17. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Parkinson's disease and mental deterioration. Apropos of 30 cases].
    Mouren P; Poinso Y; Oppenheim G; Mouren A; Nguyen Quang N
    Ann Med Psychol (Paris); 1983 Nov; 141(9):945-56. PubMed ID: 6666920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.